POZEN Inc., announced today the receipt of a $20 million milestone payment from AstraZeneca for the US Food and Drug Administration approval of VIMOVO™ delayed-release tablets on April 30 th .
POZEN announces receipt of $20 million milestone payment from AstraZeneca